^
Association details:
| Biomarker: | GOLGA5-JAK2 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure
Excerpt:
A 10-year-old Caucasian male was diagnosed with National Cancer Institute high-risk B-ALL....Sequential marrow analysis demonstrated significant clinical response to combined ruxolitinib/chemotherapy by the end of consolidation and interim maintenance 1 (IM1), although with persistent MRD ≥0.01% by FC (Figure 3A).
DOI:
10.3324/haematol.2018.192088
Source:
Title:
Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure
Excerpt:
Concomitant PDX modeling demonstrating exquisite in vivo sensitivity of GOLGA5-JAK2 ALL cells to ruxolitinib provided additional biologic validation of the child’s clinical response.
DOI:
10.3324/haematol.2018.192088
